The relationship between type 2 diabetes and dementia

British Medical Bulletin

Volumn 88, Issue 1, 2008, Pages 131-146

  Strachan, Mark W J ^a   Reynolds, Rebecca M ^b   Frier, Brian M ^c   Mitchell, Rory J ^d   Price, Jacqueline F ^d  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Cognition; Dementia; Glucocorticoids; Type 2 diabetes; Vascular disease

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; AMYLOID BETA PROTEIN; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CARBENOXOLONE; CORTISONE; CYTOKINE; FIBRINOGEN; GLUCOCORTICOID; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE; INSULIN; INTERLEUKIN 6; MEGLITINIDE; NITRENDIPINE; PERINDOPRIL; SULFONYLUREA; TUMOR NECROSIS FACTOR ALPHA;

ACUTE DISEASE; ALZHEIMER DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DIABETIC ANGIOPATHY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; HYPOGLYCEMIA; IN VIVO STUDY; INFLAMMATION; INSULIN BLOOD LEVEL; KIDNEY DISEASE; MICROANGIOPATHY; MULTIINFARCT DEMENTIA; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; RETINOPATHY; REVIEW; RISK FACTOR; SENILE PLAQUE; STROKE; WORKING MEMORY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; COGNITION DISORDERS; DEMENTIA; DIABETES MELLITUS, TYPE 2; GLUCOCORTICOIDS; HUMANS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; YOUNG ADULT;

EID: 57749169237     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldn042     Document Type: Review

References (72)

1. Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030. Diabetes Care, 27, 1047-1053.
2. Personal Social Services Research Unit. Dementia UK (2007) Available at: www.alzheimers.org.uk/News_and_Campaigns/Campaigning/PDF/ Dementia_UK_Full_Report.pdf
3. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P (2006) Risk of dementia in diabetes: a systematic review. Lancet Neurol, 5, 64-74.
4. Cukierman T, Gerstein HC, Williamson JD (2005) Cognitive decline and dementia in diabetes - systematic overview of prospective observational studies. Diabetologia, 48, 2460-2469.
5. Strachan MWJ, Deary IJ, Ewing FME, Frier BM (1997) Is type 2 (non-insulin dependent) diabetes mellitus associated with a decline in cognitive function? A critical review of published studies. Diabetes Care, 20, 438-445.
6. Zhao WQ, De Felice FG, Fernandez S et al. (2008) Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J, 22, 246-260.
7. Waring SC, Rosenberg RN (2008) Genome-wide association studies in Alzheimer disease. Arch Neurol, 65, 329-334.
8. Patterson C, Feightner JW, Garcia A, Robin Hsiung G-Y, MacKnight C, Dessa Sadovnick A (2008) Diagnosis and treatment of dementia. 1. Risk assessment and primary prevention of Alzheimer disease. CMAJ, 178, 548-556.
9. Román GC, Erkinjuntti T, Wallin A, Pantoni L, Chui HC (2002) Subcortical ischaemic vascular dementia. Lancet Neurol, 17, 426-436.
10. Chui H (2007) Subcortical ischemic vascular dementia (SIVD). Neurol Clin, 25, 717-740.
11. Fernando MS, Ince PG for the MRC Cognitive Function and Ageing Neuropathology Study Group (2004) Vascular pathologies and cognition in a population-based cohort of elderly people. J Neurol Sci, 226, 13-17.
12. Sommerfield AJ, Deary IJ, Frier BM (2004) Acute hyperglycemia alters mood state and impairs cognitive performance in people with type 2 diabetes. Diabetes Care, 27, 2335-2340.
13. Ryan CM, Fried MI, Rood JA, Cobitz AR, Waterhouse BR, Strachan MWJ (2006) Improving metabolic control leads to better working memory in adults with type 2 diabetes. Diabetes Care, 29, 345-351.
14. Abbatecola AM, Rizzo MR, Barbieri M et al. (2006) Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics. Neurology, 67, 235-240.
15. van Harten B, de Leeuw F-E, Weinstein HC, Scheltens P, Biessels GJ (2006) Brain imaging in patients with diabetes. A systematic review. Diabetes Care, 29, 2539-2548.
16. Tiehuis AM, van der Graaf Y, Visseren FL et al. (2008) Diabetes increases atrophy and vascular lesions on brain MRI in patients with symptomatic arterial disease. Stroke, 39, 1600-1603.
17. Ferguson SC, Blane A, Perros P et al. (2003) Cognitive ability and brain structure in type 1 diabetes: relation to microangiopathy and preceding severe hypoglycemia. Diabetes, 52, 149-156.
18. Wong TY, Klein R, Sharrett AR et al. (2002) Retinal microvascular abnormalities and cognitive impairment in middle-aged persons: the atherosclerosis risk in communities study. Stroke, 33, 1487-1492.
19. Ryan CM (2006) Diabetes and brain damage: more (or less) than meets the eye? Diabetologia, 49, 2229-2233.
20. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group (2007) Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med, 356, 1842-1852.
21. McGuinness B, Todd S, Passmore P, Bullock R (2006) Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst Rev, CD004034.
22. Forette F, Seux ML, Staessen JA et al. (1998) Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Sys-Eur) Trial. Lancet, 352, 1347-1351.
23. Tzourio C, Anderson C, Chapman N et al. (2003) Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med, 163, 1069-1075.
24. Scott HD, Laake K (2001) Statins for the prevention of Alzheimer's disease. Cochrane Database Syst Rev, CD003160.
25. Strachan MWJ (2003) Insulin and cognitive function. Lancet, 362, 1253 (letter).
26. Kuusisto J, Koivisto K, Mykkanen L et al. (1993) Essential hypertension and cognitive function. The role of hyperinsulinemia. Hypertension, 22, 771-779.
27. Kalmijn S, Feskens EJM, Launer LJ, Stijnen T, Kromhout D (1995) Glucose intolerance, hyperinsulinaemia and cognitive function in a general population of elderly men. Diabetologia, 38, 1096-1102.
28. Stolk RP, Breteler MMB, Ott A et al. (1997) Insulin and cognitive function in an elderly population. The Rotterdam study. Diabetes Care, 20, 792-795.
29. Craft S, Peskind E, Schwartz MW et al. (1958) Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease. Relationship to severity of dementia and Apolipoprotein E genotype. Neurology, 50, 164-168.
30. de la Monte SM, Tong M, Lester-Coll N, Plater M Jr, Wands JR (2006) Therapeutic rescue of neurodegeneration in type 3 diabetes: relevance to Alzheimer's disease. J Alzheimers Dis, 10, 89-109.
31. Deary IJ, Frier BM (1996) Severe hypoglycaemia and cognitive impairment in diabetes. Link not proven. Br Med J, 313, 767-768
32. Zammitt NN, Frier BM (2007) Hypoglycaemia in type 2 diabetes and in elderly people. In Frier BM, Fisher M (eds) Hypoglycaemia in Clinical Diabetes, 2nd ed. Chichester: John Wiley and Sons, 239-264.
33. Pirraglia PA, Gupta S (2007) The interaction of depression and diabetes: a review. Curr Diab Rev, 3, 249-251.
34. Gliebus G, Lippa CF (2007) The influence of beta-blockers on delayed memory function in people with cognitive impairment. Am J Alzheimers Dis Other Demen, 22, 57-61.
35. Phillips DI, Walker BR, Reynolds RM et al. (2000) Low birthweight predicts elevated plasma cortisol concentrations in adults from three populations. Hypertension, 35, 1301-1306.
36. Reynolds RM, Walker BR, Syddall HE et al. (2001) Altered control of cortisol secretion in adult men with low birthweight and cardiovascular risk factors. J Clin Endocrinol Metab, 86, 245-250.
37. Reynolds RM, Walker BR, Syddall HE, Hales CN, Phillips DI (2003) Predicting cardiovascular risk factors from plasma cortisol measured during glucose tolerance tests. Metabolism, 52, 524-527.
38. Reynolds RM, Walker BR, Syddall HE, Andrew R, Wood PJ, Phillips DI (2005) Is there a gender difference in the associations of birthweight and adult hypothalamic-pituitary-adrenal axis activity? Eur J Endocrinol, 152, 249-253.
39. Chiodini I, Adda G, Scillitani A et al. (2007) Cortisol secretion in patients with type 2 diabetes: relationship with chronic complications. Diabetes Care, 30, 83-88.
40. MacLullich AM, Deary IJ, Starr JM, Fergusson KJ, Wardlaw JM, Seckl JR (2005) Plasma cortisol levels, brain volumes and cognition in elderly men. Psychoneuroendocrinology, 30, 505-515.
41. Landfield PW (1981) Brain aging correlates: retardation by hormonal-pharmacological treatments. Science 214, 581-584.
42. Vallee M, Maccari S, Dellu F, Simon H, Le Moal M, Mayo W (1999) Long-term effects of prenatal stress and postnatal handling on age-related glucocorticoid secretion and cognitive performance: a longitudinal study in the rat. Eur J Neurosci, 11, 2906-2916.
43. Yau JLW, Noble J, Hibberd C et al. (2002) Chronic treatment with the antidepressant amitriptyline prevents impairments in water maze learning in aging rats. J Neurosci, 22, 1436-1442.
44. Seckl JR, Dickson KL, Yates C, Fink G (1991) Distribution of glucocorticoid and mineralocorticoid receptor messenger RNA expression in human post-mortem hippocampus. Brain Res, 561, 332-337.
45. Meaney MJ, O'Donnell D, Rowe W et al. (1995) Individual differences in hypothalamicpituitary-adrenal activity in later life and hippocampal aging. Exp Gerontol, 30, 229-251.
46. McEwan BS, Sapolsky RM (1995) Stress and cognitive function. Curr Opin Neurobiol, 5, 205-216.
47. McEwan BS (1999) Stress and the aging hippocampus. Front Neuroendocrinol, 20, 49-70.
48. Bruehl H, Rueger M, Dziobek I et al. (2007) Hypothalamic- pituitary-adrenal axis dysregulation and memory impairments in type 2 diabetes. J Clin Endocrinol Metab, 92, 2439-2445.
49. Wamil M, Seckl JR (2007) Inhibition of 11β-hydroxysteroid dehydrogenase type 1 as a novel therapeutic target. Drug Discov Today, 13-14, 504-520.
50. Sandeep TC, Yau JL, MacLullich AM et al. (2004) 11β-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics. Proc Natl Acad Sci, 101, 6734-6739.
51. Libby P, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation, 105, 1135-1143.
52. Campbell IL, Stalder AK, Chiang C-S et al. (1997) Transgenic models to assess the pathogenic actions of cytokines in the central nervous system. Mol Psychiatry, 2, 125-129.
53. Heneka MT (2006) Inflammation in Alzheimer's disease. Clin Neurosci Res, 6, 247-260.
54. Neuroinflammation Working Group (2000) Inflammation and Alzheimer's disease. Neurobiol Aging, 21, 383-421.
55. vanDijk EJ, Prins ND, Vermeer SE et al. (2005) C-reactive protein and cerebral small-vessel disease: the Rotterdam Scan Study. Circulation, 112, 900-905.
56. Rafnsson SB, Deary IJ, Smith FB et al. (2007) Cognitive decline and markers of inflammation and hemostasis: the Edinburgh artery study. J Am Geriatr Soc, 55, 700-707.
57. Schmidt R, Schmidt H, Curd JD et al. (2002) Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia aging study. Ann Neurol, 52, 168-174.
58. Engelhart MJ, Geerlings MI, Meijer J et al. (2004) Inflammatory proteins in plasma and the risk of dementia. The Rotterdam study. Arch Neurol, 61, 668-672.
59. Schram MT, Euser SM, de Craen AJM et al. (2007) Systemic markers of inflammation and cognitive decline in old age. J Am Geriatr Soc, 55, 708-716.
60. Trompet S, de Craen AJM, Slagboom P et al. (2008) Genetic variation in the interleukin-1β-converting enzyme associates with cognitive function. Brain, 131, 1069-1077.
61. Guerreiro RJ, Santana I, Bras JM (2007) Peripheral inflammatory cytokines as biomarkers in Alzheimer's Disease and mild cognitive impairment. Neurodegenerative Dis, 4, 406-412.
62. Bruunsgaard H, Anderson-Ranberg K, Jeune B et al. (1999) A high plasma concentration of TNF-α is associated with dementia in centenarians. J Gerontol A Biol Sci Med Sci, 54, M357-M364.
63. Perry VH (2004) The impact of systemic inflammation on brain inflammation. ACNR 4, 8-9.
64. Konsman JP, Parnet P, Dantzer R (2002) Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci, 25, 154-159.
65. Thal LJ, Ferris SH, Kirby L et al. Rofecoxib Protocol 078 Study Group (2005) A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology, 30, 1204-1215.
66. ADAPT Research Group (2008) Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of Naproxen and Celecoxib. Arch Neurol, 65: 896-905.
67. Richards M, Meade TW, Peart S et al. (1997) Is there any evidence for a protective effect of antithrombotic medication on cognitive function in men at risk of cardiovascular disease? Some preliminary findings. J Neurol Neurosurg Psychiatry, 62, 269-272.
68. Kang JH, Cook N, Manson J et al. (2007) Low dose aspirin and cognitive function in the women's health study cognitive cohort. Br Med J, 334, 987-990.
69. Price JF, Stewart M, Deary IJ, on behalf of the AAA Trialists (2008) Randomised controlled trial of low dose aspirin and cognitive function in middle aged to elderly adults. Br Med J, 337: a1198.
70. Davey Smith G, Ebrahim S (2003) 'Mendelian Randomisation': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol, 32, 1-22.
71. Strachan MWJ, Price JF, Frier BM (2008) Diabetes, cognitive impairment and dementia. Br Med J, 336, 6.
72. Williamson JD, Miller ME, Bryan RN et al. (2007) The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design and methods. Am J Cardiol, 99, 112i-122i.